Loading patent…
OwnerRaghuraman Kannan, Ajit Prakash Zambre +2inventors
InventorsRaghuraman Kannan, Ajit Prakash Zambre, Anandhi Upendran, Henry White
Estimating the term…
A preferred embodiment is a method of formation of nanoparticle conjugates for cancer diagnostics, imaging and therapy, wherein the method allows determination a priori the efficacy of the nanoparticle conjugate for treatment of disease. A preferred stable pharmaceutical formulation includes a single antibody agent retaining its functionality in accordance with a predetermination of an a priori efficacy and electrostatically or covalently linked to a nanoparticle in a predetermined ratio in accordance with the a priori efficacy. Preferred embodiments also provide a method for forming single human antibody nanoparticle conjugates. The methods retain properties of the human antibody with a fabrication process that also allows control of the bonding mode of the antibody to the surface of AuNP, such that the bonding mode can be predetermined to be either electrostatic or covalent.
1) A stable pharmaceutical formulation comprising a single antibody agent retaining its functionality in accordance with a predetermination of an a priori efficacy and electrostatically or covalently linked to a nanoparticle in a predetermined ratio in accordance with the a priori efficacy.
11) The formulation of claim 11, wherein the linker is one of monoethylene glycol, diethylene glycol, and polyethylene glycol.
15) A method of formation of nanoparticle conjugates for cancer diagnostics, imaging and therapy, wherein the method allows determination a priori the efficacy of the nanoparticle conjugate for treatment of disease, comprising synthesis of nanoparticles in solution, attachment of a linker to the nanoparticles, selective electrostatic or covalent coupling of a single antibody agent to the nanoparticles, and physicochemical characterization of the formed nanoconjugate.
Dependencies are inferred from the claim text.